Meeting report: cGMP matters.
The second messenger cyclic guanosine 3',5'-monophosphate (cGMP) controls many cellular functions ranging from growth to contractility. Generated from guanylyl cyclases in response to natriuretic peptides or nitric oxide, cGMP transduces its effects through a number of cGMP effectors, including cGMP-regulated phosphodiesterases and protein kinases. Drugs that modulate cGMP levels are emerging as promising therapies, particularly for cardiovascular disorders. This report summarizes new data on the molecular mechanisms, (patho)physiological relevance, and therapeutic potential of the cGMP signaling system that were presented at the 3rd cGMP meeting held in June 2007 in Dresden, Germany.
Kemp-Harper
Barbara
B
Department of Pharmacology and Centre for Vascular Health, Monash University, Clayton, Victoria, Australia. Barbara.Kemp@med.monash.edu.au
Feil
Robert
R
D000818:Animals; D002319:Cardiovascular System / Q000378:metabolism; D006152:Cyclic GMP / Q000502:physiology*; D015195:Drug Design; D006801:Humans; D008954:Models, Biological; D010455:Peptides / Q000737:chemistry; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D015398:Signal Transduction
D010455:Peptides; D010726:Phosphodiesterase Inhibitors; D006152:Cyclic GMP